Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 33, 28, 5, 95, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 4 molecules, respectively.
Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Obstructive Pulmonary Disease (COPD) - Overview
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
Featured News & Press Releases
Aug 09, 2022: Dimerix announces new patent family application for DMX-700
Aug 09, 2022: Verona Pharma to announce top-line data from Phase 3 ENHANCE-2 Trial of nebulized ensifentrine for COPD
Aug 09, 2022: Verona Pharma announces ensifentrine meets primary endpoint in phase 3 ENHANCE-2 trial for COPD
Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
Jul 04, 2022: DMX-700 shows significant efficacy with 80% reduction in lung injury of COPD
Jun 09, 2022: Verona Pharma completes enrollment in phase 3 ENHANCE-1 trial evaluating ensifentrine for maintenance treatment of COPD
Jun 06, 2022: Verona Pharma to host KOL event on June 16, 2022
May 23, 2022: Therapeutic Solutions International receives IND number 28508 for Chronic Obstructive Pulmonary Disease clinical trial and enters binding discussions with FDA for initiation of phase I/II Clinical Trial
May 18, 2022: Successful completion of phase I study for lead asset EP395
May 18, 2022: Verona Pharma to present successful TQT analysis demonstrating no clinically relevant effect on cardiac conduction at the American Thoracic Society 2022
May 12, 2022: Phase III lung Adult Stem Cell company announces and files patent on leukine-induced myeloid derived suppressor cells and JadiCell for treatment of COPD
May 09, 2022: Therapeutic Solutions International files Investigational New Drug application for treatment of Chronic Obstructive Pulmonary Disease (COPD) using JadiCell universal donor adult stem cells
Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
Mar 28, 2022: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver
Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, 2022
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 33, 28, 5, 95, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 4 molecules, respectively.
Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Obstructive Pulmonary Disease (COPD) - Overview
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
Featured News & Press Releases
Aug 09, 2022: Dimerix announces new patent family application for DMX-700
Aug 09, 2022: Verona Pharma to announce top-line data from Phase 3 ENHANCE-2 Trial of nebulized ensifentrine for COPD
Aug 09, 2022: Verona Pharma announces ensifentrine meets primary endpoint in phase 3 ENHANCE-2 trial for COPD
Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
Jul 04, 2022: DMX-700 shows significant efficacy with 80% reduction in lung injury of COPD
Jun 09, 2022: Verona Pharma completes enrollment in phase 3 ENHANCE-1 trial evaluating ensifentrine for maintenance treatment of COPD
Jun 06, 2022: Verona Pharma to host KOL event on June 16, 2022
May 23, 2022: Therapeutic Solutions International receives IND number 28508 for Chronic Obstructive Pulmonary Disease clinical trial and enters binding discussions with FDA for initiation of phase I/II Clinical Trial
May 18, 2022: Successful completion of phase I study for lead asset EP395
May 18, 2022: Verona Pharma to present successful TQT analysis demonstrating no clinically relevant effect on cardiac conduction at the American Thoracic Society 2022
May 12, 2022: Phase III lung Adult Stem Cell company announces and files patent on leukine-induced myeloid derived suppressor cells and JadiCell for treatment of COPD
May 09, 2022: Therapeutic Solutions International files Investigational New Drug application for treatment of Chronic Obstructive Pulmonary Disease (COPD) using JadiCell universal donor adult stem cells
Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
Mar 28, 2022: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver
Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, 2022
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Related Report
